以颊黏膜多发玫瑰疹为特征的伤寒一例

患者男,14岁.因持续发热1周入院.7 d前无明显诱因出现低热,37.8℃,自服感冒药无效,体温逐日升高达39.6℃,伴畏寒、食欲明显减退、腹胀、便秘,无寒战,无汗.体格检查:体温39.8℃,脉搏92次/min,血压110/70 mmHg(1 mm Hg=0.133 kPa).     

混合物脑肽干预对肝纤维化大鼠模型的影响

背景:混合物脑肽是从动物脑中提取的多肽混合物,含有神经生长因子成分。近年研究发现,神经生长因子与肝损伤密切相关。目的:使用自拟混合物脑肽观察对大鼠肝纤维化的影响。方法:利用四氯化碳诱导形成SD大鼠肝纤维化模型。将大鼠随机分成纤维化模型组、脑肽干预组和对照组。4,8周采集标本。通过活体解剖取门静脉血清采用全自动生化分析仪检测肝功能丙氨酸氨基转移酶、天冬氨酸氨基转移酶、总胆红素、白蛋白;采用放射免疫法检测血清肝纤维化指标透明质酸、层粘连蛋白、Ⅲ型前胶原;常规苏木精-伊红和网状纤维染色检测肝组织标本。结果与结论:大鼠肝纤维化模型成功建立。脑肽干预组纤维化程度较纤维化模型组显著减轻,但肝组织炎症和肝细胞脂肪变性反而较纤维化模型组更显著。初步判断脑肽能够阻断四氯化碳诱导的肝纤维化,可能与神经生长因子有关。     

抗结核药物肝毒性危险因素研究进展

目前结核病死灰复燃且有上升的趋势,每年有150万人因结核病死亡[1].由于抗结核治疗时间长并且多种药物同时使用,副作用成为一个严重的临床问题.肝损伤被认为是抗结核药物最严重的副作用,因为抗结核治疗期间,肝损伤发生率和死亡率都较其他副作用显著增高[2].然而,抗结核药物肝毒性(antibuberculosis drug-induced hepatototoxicity,ATDH)的发生存在显著的个体差异.不同的人群由于遗传素质等因素的差异,ATDH的发生有明显的不同;而在遗传素质相似的人群中,年龄及性别等因素也会对ATDH的发生产生影响.本文就近年来对ATDH相关危险因素的研究进展进行概括总结.     

流行性出血热并发视网膜色素上皮炎一例

流行性出血热并发视网膜色素上皮炎一例孙水林（第二附属医院传染科南昌３３０００６）１临床资料患者，男，４４岁。１９８８年１月１２月，因发热，头痛，腰痛５ｄ，眼球结膜水肿，口腔粘膜及双腋下皮肤见比较多针尖样出血点，查尿蛋白（），血Ｒｔ：ＷＢＣ２．１×１...     

肾综合征出血热相关细胞因子研究进展

肾综合征出血热(hemorrhagic fever with renal syndrome,HFRS)是汉坦病毒感染引起的以发热、休克、充血、出血和急性肾功能衰竭为主要表现的一种自然疫源性疾病,其基本病变为全身广泛性小血管损害,典型病例临床上有5期病程:发热期、低血压休克期、少尿期、多尿期和恢复期.     

《人体形态学》网络教学中护生实践能力及创新精神培养的研究

在护理专业教学改革中，把人体系统解剖学、组织胚胎学和局部解剖学三门课程合并成一门人体形态学，并且把现代教育技术的手段与传统的教学方法有机的结合。为培养高素质现代医学人才，以转变教育教学思想为先导，以现代教育技术作为依托．对人体形态学课程的教学内容、教学方法、教学手段进行整体改革，在实践中逐步构建和完善利用多媒体的理论课教学、实验教学以及网络自主学习三者有机结合的现代人体形态学课程网络教学体系。     

甲状腺区辨认喉返神经的解剖数据

本文在100侧(50具)成人尸体上,从临床应用的角度,调查了喉返神经在甲状腺区的毗邻关系,提出了在甲状腺手术中辨认喉这神经的解剖数据和临床标志,为保护喉返神经提供了可靠的解剖数值依据。     

急性肝功能衰竭与基因相关性

急性肝功能衰竭目前没有特异性治疗,病死率极高。随着对基因研究的深入,在急性肝功能衰竭的发生和治疗方面提供了新的思路,此文就急性肝功能衰竭与基因的相关问题进行综述。     

Clinical study of the efficacy of interferon-α therapy for HBeAg-negative chronic hepatitis B patients

Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB.     

Clinical study of the efficacy of interferon-α therapy for HBeAg-negative chronic hepatitis B patients

Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB.